Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Update

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 6,800 shares, a growth of 112.5% from the December 31st total of 3,200 shares. Based on an average daily volume of 16,400 shares, the short-interest ratio is currently 0.4 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Adlai Nortye in a research note on Monday, November 11th.

Adlai Nortye Stock Performance

Shares of Adlai Nortye stock opened at $2.08 on Wednesday. The business has a 50-day moving average of $2.22 and a 200 day moving average of $2.49. Adlai Nortye has a 12 month low of $1.85 and a 12 month high of $17.48.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.